lyophilized powder comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
==== History of opium production ==== Despite the social and cultural costs, communities in Guerrero such as La Sierra and La Montaña have continuously relied on the illegal opiate market as their primary source of income. Historical dispossession in Guerrero has weakened economic stability in under-developed regions including Atoyac de Álvarez and Ayutla de los Libres.
gonadotropins (luteinizing hormone and follicle-stimulating hormone) glycoprotein IIb/IIIa, an integrin found on platelets that is required for normal platelet aggregation and adherence to the endothelium. components of the zona pellucida, which surrounds the oocyte, and is important for sperm-egg interaction. structural glycoproteins, which occur in connective tissue. These help bind together the fibers, cells, and ground substance of connective tissue. They may also help components of the tissue bind to inorganic substances, such as calcium in bone. Glycoprotein-41 (gp41) and glycoprotein-120 (gp120) are HIV viral coat proteins. Soluble glycoproteins often show a high viscosity, for example, in egg white and blood plasma.
In April 2019, Collins began filming for her own reality series, Gemma Collins: Diva Forever. The series premiered in August 2019 on ITVBe. The pilot episode premiered to a total of 673,038 viewers, and was the most watched episode on ITVBe in that week. The same month, Collins began hosting a podcast on BBC Sounds, titled The Gemma Collins Podcast. It was also reported that Collins had signed a record deal with Universal Music Group, and was set to release a single with Naughty Boy after the pair met at the BRIT Awards 2019 and had been impressed by Collins' vocal ability, however plans for this never materialised. Diva Forever was subsequently renewed by ITV for a second series, but due to the COVID-19 pandemic, production was suspended. As a result, Collins filmed a new reality series, Gemma Collins: Diva on Lockdown, which featured Collins and her family in lockdown and aired between April and May 2020. In August 2020, Collins began hosting a second podcast on BBC Sounds entitled The Gemma Collins Love Lounge. In October 2020, Gemma Collins: Diva Forever & Ever premiered on ITVBe. In December 2020, Collins released a charity single, a cover of "Baby, It's Cold Outside" alongside her Celebrity Big Brother co-star Darren Day, with proceeds from the single going towards Rethink Mental Illness. The music video was released at the end of Gemma Collins: Diva for Xmas, which aired two days prior to the single's release and transpired to be the final episode of the show.
The maximum recommended dose should not exceed three times the original vortioxetine dose. Vortioxetine and its metabolites show no meaningful interactions with a variety of assessed cytochrome P450 enzymes and transporters (e.g., P-glycoprotein), hence vortioxetine is not expected to influence the pharmacokinetics of other medications importantly. The combination of vortioxetine with MAOIs, including other MAOIs such as linezolid and intravenous methylene blue, may cause serotonin syndrome and is contraindicated. The risk of serotonin syndrome may also be increased when vortioxetine is combined with other serotonergic drugs, like SSRIs, SNRIs, tricyclic antidepressants (TCAs), triptans, tramadol, tryptophan, buspirone, St John's wort, fentanyl, and lithium, among others. However, vortioxetine is not considered to be contraindicated with serotonergic medications besides MAOIs.
Requires Supplemental Nutrition Assistance Program (federal food assistance) beneficiaries ages 18 to 64 to work at least 80 hours per month, compared to ages 18 to 54 under current law; Requires states with an error rate above 6% to contribute to up to 15% of SNAP benefit costs. Alaska and Hawaii received special exemptions for these effective cuts after lobbying from senators Lisa Murkowski and Dan Sullivan; Repeals the National Education and Obesity Prevention Grant Program; Reduces federal nutrition funding by $186 billion between 2025 and 2034. Increases the share of state costs to administer the SNAP program from 50% to 75%; and Restricts future updates to the Thrifty Food Plan used to calculate SNAP benefit levels.
Sources: en.wikipedia.org
In July 2023, TikTok launched a new streaming service called TikTok Music. This service allowed users to listen to, download and share songs. After a dispute with TikTok regarding payouts for artists and regulation of AI-generated music content on the platform, Universal Music Group decided not to renew its licensing agreement, causing its catalogue of 3 million recordings to become unavailable for usage after 2024. This marked the company's first instance of withdrawing its music from a major platform, in contrast to Warner Music, which had recently renewed its own licensing deal with TikTok. In March 2024, Universal Music Publishing Group removed its catalogue of 4 million compositions from TikTok. In April 2024, Taylor Swift's music returned to the platform. TikTok Music was discontinued in November 2024. In December 2025, TikTok launched digital gift cards. In February 2026, TikTok launched Local Feed, a feature intended to help users connect with their community and discover local events and updates. In June 2026, TikTok launched Agentic Hub, a platform that integrates third-party AI applications with its advertising system to support campaign creation, management, and performance evaluation. In July 2026, TikTok introduced new AI literacy measures, including educational guides and enhanced content transparency tools, to help users recognize AI-generated content. In August 2026, TikTok introduced a legacy account setting that allows users to decide what happens to their account after their death.
=== Category:EC 1.2 (act on the aldehyde or oxo group of donors) === Category:EC 1.2.1 (with NAD+ or NADP+ as acceptor) Acetaldehyde dehydrogenase EC 1.2.1.10 Glyceraldehyde 3-phosphate dehydrogenase EC 1.2.1.12 Pyruvate dehydrogenase EC 1.2.1.51 Category:EC 1.2.4 Oxoglutarate dehydrogenase EC 1.2.4.2
Early in 1953 Watson and Crick proposed a correct structure for the DNA double helix. Pauling later cited several reasons to explain how he had been misled about the structure of DNA, among them misleading density data and the lack of high quality X-ray diffraction photographs. Pauling described this situation as "the biggest disappointment in his life". During the time Pauling was researching the problem, Rosalind Franklin in England was creating the world's best images. They were key to Watson's and Crick's success. Pauling did not see them before devising his mistaken DNA structure, although his assistant Robert Corey did see at least some of them, while taking Pauling's place at a summer 1952 protein conference in England. Pauling had been prevented from attending because his passport was withheld by the State Department on suspicion that he had Communist sympathies. This led to the legend that Pauling missed the structure of DNA because of the politics of the day (this was at the start of the McCarthy period in the United States). Politics did not play a critical role. Not only did Corey see the images at the time, but Pauling himself regained his passport within a few weeks and toured English laboratories well before writing his DNA paper. He had ample opportunity to visit Franklin's lab and see her work, but chose not to. Despite these times, Pauling chose to move on from them and be thankful for the discoveries that he had already found.
Their keenest sense is smell, which is about seven times more sensitive than a domestic dog's. They are excellent and strong swimmers, swimming for pleasure and to feed (largely on fish). They regularly climb trees to feed, escape enemies and hibernate. Four of the eight modern bear species are habitually arboreal (the most arboreal species, the American and Asian black bears and the sun bear, being fairly closely related). Their arboreal abilities tend to decline with age. They may be active at any time of the day or night, although they mainly forage by night. Bears living near human habitations tend to be more extensively nocturnal, while those living near brown bears tend to be more often diurnal. American black bears tend to be territorial and non-gregarious in nature. However, at abundant food sources (e.g. spawning salmon or garbage dumps), they may congregate and dominance hierarchies form, with the largest, most powerful males dominating the most fruitful feeding spots. They mark their territories by rubbing their bodies against trees and clawing at the bark. Annual ranges held by mature male bears tend to be very large, though there is some variation. On Long Island off the coast of Washington, ranges average 5 sq mi (13 km2), whereas on the Ungava Peninsula in Canada ranges can average up to 1,000 sq mi (2,600 km2), with some male bears traveling as far as 4,349 sq mi (11,260 km2) at times of food shortages. Bears may communicate with various vocal and non-vocal sounds.
Protein S aids this process by catalysing the proteolysis at Arg306, in which the A2 domain of Factor V is dissociated from the rest of the protein. Protein S also binds to Factor Xa, inhibiting the latter from diminishing APC's inactivation of Factor Va. The inactivation of Factor VIIIa is not as well understood. The half-life of Factor VIIIa is only around two minutes unless Factor IXa is present to stabilise it. Some have questioned the significance of APC's inactivation of Factor VIIIa, and it is unknown to what degree Factor V and protein S are cofactors in its proteolysis. It is known that APC works on Factor VIIIa by cleaving at two sites, Arg336 and Arg562, either of which is sufficient to disable Factor VIIIa and convert it to Factor VIIIi.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.